The study reflects the importance of including multiple biomarkers for diagnostic and treatment decisions associated with pneumonia, IVD industry experts said.
The company said it plans to move all its immunoassays to a single vendor, representing an opportunity worth between $250 million and $400 million annually.
The company's revenues were driven by its centralized and point-of-care solutions as well as its molecular diagnostics business, both rising in the single digits.
The FDA gave the nod to Shenzhen Bioeasy Biotechnology for two lateral flow immunoassays that provide preliminary results in detecting marijuana in urine.
The platform developed during an initiative managed by BioMed X with input from Roche uses field effect sensors to detect several different types of analytes.
According to Natera CEO Steve Chapman, the agreement will not detract from Natera's own efforts to establish its exome sequencing-based Signatera assay.
Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs.
The companies will use Foundation Medicine's FoundationOne CDx test as the baseline to define a set of unique variants that the codeveloped assays will monitor.
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.
The blood test screens individual blood donations for four common species of the parasite Babesia, which can cause anemia and other potentially fatal conditions.